Pinnacle MHN contract directly with Waikato community podiatrists to provide care for patients with diabetes who have had a foot check that determines they are high risk. This care is provided across the region.
This is a referral service only. It is not a claimable service.
This is NOT a clinical guideline.
Any Pinnacle practice in Waikato can refer to this service.
All patients who have had a foot check that determines they are high risk can have an initial appointment at which point both clinical judgement and their ability to self-manage and self-fund will determine further treatment. Sessions are capped at 4 per patient per year to ensure sustainability of the service.
Practices are required to submit an e-Referral requesting a package of care for their patient.
Patients with diabetes who have had a foot check that determines they are high risk.
Once the patient has been accepted into the service, they can continue receiving 4 funded podiatry sessions each year. They do not need to be referred again.
This is not a claimable service; this is a free service that you can refer patients to.
Practices are required to submit an e-Referral requesting a package of care for their patient.
Please ensure the foot check details are attached to the e-Referral.
No. There is no charge to the patients for this referral service.
The service is funded by Waikato DHB.
Sally Newell, Regional Support Manager - Clinical Contracts
sally.newell@pinnacle.health.nz
021 150 8788
Pinnacle MHN contract directly with Waikato community podiatrists to provide care for patients with diabetes who have a high-risk foot.
Referral pathways for low, moderate, high and active risk diabetes foot screening and assessment.
Kathy joined Pinnacle earlier this month as clinical diabetes specialist for Waikato, replacing the role previously held by Anne Waterman.
Read morePharmac is now allowing new special authority applications for liraglutide (Victoza) from 1 March 2025. The special authority criteria will be the same as when special authorities were suspended in May 2024. This will again allow prescribing according to national guidelines and best practice. Pharmac has assured the intention is for no further suspensions of special authority criteria for GLP-1 agonists to allow ongoing access for those who meet criteria. To ensure availability, it continues to be important these medications are only prescribed for people with type 2 diabetes mellitus (T2DM). Please contact the Pinnacle diabetes lead in your area if you have any questions.
Read moreThe clinical diabetes specialist in primary care provides clinical mentorship and advice to the practice team in supporting patients with diabetes.
View detailsA guide for clinical management of type 2 diabetes, to support nurses at all levels to develop their knowledge and clinical reasoning in diabetes care.